Endogenous retroviruses (ERV) are potential etiologic agents in human and murine autoimmunity. A class of ERV, Mpmv, is transcribed in thymuses of 5 lupus-prone but in none of 11 control mouse strains. In lupus-prone mice, thymus Mpmv RNA expression is abnormal from day one of life, suggesting that it may be closely linked to genes which predispose to autoimmunity. To determine whether the proteins encoded by Mpmv directly contribute to autoimmunity, their expression will be blocked in transgenic lupus mice. Our preliminary data and published reports from four different groups targeting other genes (including a retrovirus) indicate the potential utility of antisense RNA for manipulating Mpmv expression in transgenic mice. Using a T cell line that highly expresses Mpmv RNA and protein, we will test multiple constructs expressing antisense RNA to different Mpmv sequences under different promoters and enhancers. Initially, we will focus on the CMV-based vector previously used successfully in transgenic mice to protect against infectious retrovirus by expressing antisense RNA. The most promising vectors identified by stable transfection into the T cell line will be used to generate transgenic lupus-prone mice, which will then be studied to determine if the disease phenotype has been altered. Previous genetic studies using recombinant inbred and backcross mice have demonstrated that several autoimmune traits segregate independently. To determine whether thymus Mpmv RNA expression may cosegregate with a particular feature of autoimmunity, we will perform Northern analyses of well-characterized recombinant inbred lines between lupus-prone NZB and control SM/J mice. Finally, the present application will pursue our preliminary studies which indicate that Mpmv transcription results from a dysregulation of gene expression in lupus. The DNA sequences responsible for abnormal Mpmv transcription in lupus-prone mice will be identified and characterized. Since abnormal gene regulation in lupus is not well understood, studies of the regulation of Mpmv expression could lead to new insights into the molecular genetic defects of human and murine lupus.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29AR042556-02
Application #
2081906
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Project Start
1993-12-10
Project End
1998-11-30
Budget Start
1994-12-01
Budget End
1995-11-30
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Iowa
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041294109
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Kovarik, J; Bozzotti, P; Love-Homan, L et al. (1999) CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol 162:1611-7
Yi, A K; Krieg, A M (1998) CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I kappa B alpha and I kappa B beta and sustained activation of nuclear factor-kappa B/c-Rel. J Immunol 160:1240-5
Davis, H L; Weeratna, R; Waldschmidt, T J et al. (1998) CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160:870-6
Krieg, A M; Love-Homan, L; Yi, A K et al. (1998) CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol 161:2428-34
Redford, T W; Yi, A K; Ward, C T et al. (1998) Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides. J Immunol 161:3930-5
Yi, A K; Chang, M; Peckham, D W et al. (1998) CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol 160:5898-906
Krieg, A M; Wu, T; Weeratna, R et al. (1998) Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A 95:12631-6
Moldoveanu, Z; Love-Homan, L; Huang, W Q et al. (1998) CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16:1216-24
Yi, A K; Tuetken, R; Redford, T et al. (1998) CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol 160:4755-61
Weeratna, R; Brazolot Millan, C L; Krieg, A M et al. (1998) Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev 8:351-6

Showing the most recent 10 out of 24 publications